Key result
Moxonidine showed comparable blood pressure reduction to enalapril but additionally normalized the 24-hour BP profile and reduced BP variability in patients with metabolic syndrome.
Why the study?
The study was conducted to evaluate the efficacy of the imidazoline receptor agonist moxonidine compared to the ACE inhibitor enalapril in patients with arterial hypertension and metabolic syndrome.
Does moxonidine improve blood pressure control and vascular parameters compared to enalapril in patients with arterial hypertension and metabolic syndrome?
RCT (n=50)
randomized
Does moxonidine improve blood pressure control and vascular parameters compared to enalapril in patients with arterial hypertension and metabolic syndrome?
In patients with hypertension and metabolic syndrome, moxonidine provides comparable blood pressure lowering to enalapril but offers additional benefits on blood pressure variability and cerebrovascular reactivity.
Answers are grounded in this paper and cite their sources.
Moxonidine may warrant preference over enalapril for normalized 24-hour BP in metabolic syndrome hypertension; extends RCT evidence on variability reduction.
Purpose. To evaluate the efficacy of moxonidine, an imidazoline receptor agonist, in patients with arterial hypertension (AH) and metabolic syndrome compared to enalapril, an ACE inhibitor. Materials and methods. The complex study included 50 patients with AH and metabolic syndrome. Inclusion criteria were abdominal obesity (waist-to-hip ratio (WHR) exceeded 0.95 in men and exceeded 0.80 in women, with BMI ≥25 kg/m 2 , AH of 1st - 2-nd degrees, type 2 diabetes mellitus (DM) in the stage of compensation, dyslipidemia. The mean age of patients was 52 years, duration of AH is 11 years, duration of type 2 DM is 7 years. After examination under conditions of a pure background and obtaining of DM compensation, all patients with AH and metabolic syndrome were randomized into 2 groups. The first group of patients (25 people) received moxonidine, an imidazoline receptor agonist, in individually selected dose of 0.2-0.6 mg per day, an average daily dose of 0.4 mg in twice a day form. The second group (25 people) took enalapril, an ACE inhibitor, in a dose of 5-15 mg per day, an average dose of 10 mg, respectively. A control study was performed after 4 weeks. Results. In patients with AH and metabolic syndrome, the use of moxonidine and enalapril for the correction of blood pressure (BP) showed a comparable effect in changes of office BP, average 24-hour BP, average day-time and night-time BP with the same frequency of achieving target BP. However, only moxonidine showed additional positive effect on the increased BP variability, contributed to the normalization of 24-hour BP profile, reducing the morning rise in BP, reduced the frequency of heart rate and the value of the double product. Moreover, moxonidine had cerebroprotective effects, increasing the cerebrovascular reactivity index. Conclusion. In hypertensive patients with metabolic syndrome, moxonidine provides the best prevention of cardiovascular complications.
No takes yet. Share an insight, caveat, or question.
Гапон et al. (2019) conducted an RCT in Arterial hypertension and metabolic syndrome (n=50). Moxonidine vs. Enalapril (5-15 mg per day) was evaluated on Changes in office BP, average 24-hour BP, average day-time and night-time BP. Moxonidine showed comparable blood pressure reduction to enalapril but additionally normalized the 24-hour BP profile and reduced BP variability in patients with metabolic syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: